Table 2 Survival of target tumor MDA/MB-361 cells incubated with breast cancer patients PBMC in nutrient medium with 10% pooled serum (Nc) or with 10% of autologous serum (Na) without or with 21 μg/ml Herceptin (Na+H). Effectors (E) to target tumor cells (T) ratio was 5:1.
From: The antitumor immune response in HER-2 positive, metastatic breast cancer patients
Patient | S N (%) | S Na (%) | S Na+H (%) | CD16 (%) |
|---|---|---|---|---|
1 | 73 | 30 | 21 | 32.02 |
2 | 42 | 39 | 13 | 18.98 |
3 | 73 | 69 | 30 | 16.68 |
4 | 49 | 27 | 24 | 25.76 |
5 | 87 | 23 | 12 | ND |
6 | 69 | 62 | 49 | ND |
7 | 55 | 33 | 5 | 28.00 |
8 | 53 | 11 | 8 | 25.32 |
9 | 49 | 40 | 11 | 5.47 |
10 | 51 | 57 | 33 | 4.84 |
11 | 24 | 34 | 13 | ND |
12 | 70 | 32 | 10 | ND |
13 | 40 | 35 | 19 | 11.81 |
14 | 74 | 14 | 9 | 25.59 |